Mainsail Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Mainsail Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$204K	Buy	456 +2	+0.4%	+$933	0.09%	109
2025 Q4	$206K	Buy	+454	New	+$196K	0.09%	100
2025 Q3	–	Sell	-462	Closed	-$206K	–	93
2025 Q2	$206K	Hold	462	–	–	0.13%	57
2025 Q1	$224K	Buy	+462	New	+$215K	0.15%	53
2024 Q4	–	Sell	-450	Closed	-$209K	–	69
2024 Q3	$209K	Hold	450	–	–	0.16%	58
2024 Q2	$211K	Buy	+450	New	+$195K	0.17%	51

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Mainsail Asset Management's VRTX Position: Q1 2026 in Review

Mainsail Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 0.44% in Q1 2026, buying an estimated $933 and bringing the position to 456 shares worth $204K. The position accounts for 0.09% of the portfolio, ranked #109.

Mainsail Asset Management first reported a position in VRTX in Q2 2024 and has held it in 6 quarters since. The position peaked at $224K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Mainsail Asset Management held 456 shares of Vertex Pharmaceuticals worth $204K as of Q1 2026.
Mainsail Asset Management bought 2 Vertex Pharmaceuticals shares in Q1 2026, an estimated $933.
Vertex Pharmaceuticals made up 0.09% of Mainsail Asset Management's portfolio in Q1 2026, its #109 holding.
Mainsail Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 6 quarters since.
Mainsail Asset Management's Vertex Pharmaceuticals position peaked at $224K in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Mainsail Asset Management's 13F filing for Q1 2026, filed 13 May 2026.